TransCode Therapeutics, Inc.
RNAZ
$6.97
-$0.235-3.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -104.28% | -154.85% | 55.28% | -56.03% | 18.61% |
| Total Depreciation and Amortization | -58.34% | -3.61% | -10.71% | 0.85% | 1.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 451.09% | 733.45% | -82.12% | 524.24% | -40.96% |
| Change in Net Operating Assets | -148.30% | 149.00% | -222.92% | 267.30% | 53.85% |
| Cash from Operations | 1.58% | 19.59% | -67.22% | 40.57% | 30.48% |
| Capital Expenditure | -- | 96.12% | -180.43% | -21.05% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 96.12% | -180.43% | -21.05% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 25.03% | 189.44% | 211.61% | -87.10% | 522.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.03% | 189.44% | 211.61% | -87.10% | 522.28% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.32% | 366.13% | 5.16% | -172.65% | 145.80% |